STING1 and amyotrophic lateral sclerosis: These patients have higher systemic type 1 IFN levels than sporadic patients of ALS and FTD due to overactive cGAS-STING signaling (in the absence of its negative regulator c9orf72) that can be reversed by the STING inhibitor.